[Sevikar or Forzaten: olmesartan medoxomil and amlodipine besylate fixed combination in the treatment of hypertension].
The interest for powerful and better tolerated antihypertensive combinations is searched in the field of hypertension, because of a too large number of people still not well controlled. The recent association between an angiotensin receptor blocker, olmesartan, and a long-acting dihydropyridine, amlodipine, reinforces our therapeutic possibilities. The synergistic effect of the two molecules potentiate the antihypertensive activity, which allows improving the quality and the rapidity of the blood pressure control. Furthermore, the fixed combination should improve patient's compliance. The contraindications still remain those of the sartan family. The most frequent side-effect of amlodipine monotherapy, oedema, occurs in a much lower proportion with the addition of olmesartan.
Krzesinski
J M
JM
Université de Liège, Belgique. jm.krzesinski@chu.ulg.ac.be
Scheen
A J
AJ
D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D000068557:Olmesartan Medoxomil; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D004338:Drug Combinations; D007093:Imidazoles; D013777:Tetrazoles; D017311:Amlodipine; D000068557:Olmesartan Medoxomil